Drugs / Pegylated L-Asparaginase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00905034 | Mar 2009 → Feb 2015 | acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03150693 Background | Sep 2017 → Mar 2027 expected | B-cell acute lymphoblastic leukemia | Alliance for Clinical Trials in Oncology | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated L-Asparaginase | “Pegylated-L-asparaginase is designed to get rid of an important building block of proteins in leukemia cells.” NCT00905034 ↗ |
| Route | Intravenous | “Given IV” NCT03150693 ↗ |